Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTB101 and sirolimus in mild Parkinson's disease
ACTRN12619000372189Phase 2Recruiting
- Sponsor
- resTORbio
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of dactolisib and sirolimus in Parkinson's disease (PD) (6 arms), sponsored by resTORbio. Primary endpoints: Treatment-emergent adverse events and Clinically significant changes in laboratory and clinical parameters. Started Mar 2019; status: recruiting.
02
Drugs
dactolisibsirolimus
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ACTRN12619000372189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000372189.